Insight Molecular Diagnostics Inc. (IMDX) Return on equity 2020–2023
Insight Molecular Diagnostics Inc. (IMDX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-0.1%FY2023 · since FY2020: -89.4% → -0.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2023 | -0.1% | +212.5 pp |
| FY2022 | -212.6% | -114.3 pp |
| FY2021 | -98.3% | -8.9 pp |
| FY2020 | -89.4% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice